Gilling Lucia, Suwattee Pitiporn, DeSouza Cyrus, Asnani Sunil, Fonseca Vivian
Section of Endocrinology, Department of Medicine, Tulane University Medical School, New Orleans, Louisiana 70112, USA.
Am J Cardiovasc Drugs. 2002;2(3):149-56. doi: 10.2165/00129784-200202030-00002.
Rosiglitazone and pioglitazone are medications from the thiazolidinedione class of compounds currently available for the treatment of type 2 diabetes mellitus. Traditionally used to enhance insulin sensitivity and decrease plasma insulin levels, added applications have emerged beyond those involving glycemic control. Cardiovascular risk factors associated with insulin resistance such as elevated blood pressure, dyslipidemia, abnormal fibrinolysis, and endothelial and vascular dysfunction have been shown to improve after thiazolidinedione treatment. Therapy with rosiglitazone or pioglitazone has been found to modify vascular reactivity and other processes involved in atherosclerosis. There may be differences between the agents in their effects on plasma lipid characteristics and particle size. These agents serve as excellent adjuncts to oral and insulin therapy for patients with type 2 diabetes mellitus and hold promise for the prevention of cardiovascular disease associated with the insulin resistance syndrome. Clinical trials are in progress to determine whether such therapy will lead to a reduction in cardiovascular events.
罗格列酮和吡格列酮是目前可用于治疗2型糖尿病的噻唑烷二酮类化合物药物。传统上用于增强胰岛素敏感性和降低血浆胰岛素水平，除了血糖控制之外，还出现了其他应用。与胰岛素抵抗相关的心血管危险因素，如血压升高、血脂异常、纤维蛋白溶解异常以及内皮和血管功能障碍，在噻唑烷二酮治疗后已显示有所改善。已发现使用罗格列酮或吡格列酮进行治疗可改变血管反应性以及动脉粥样硬化涉及的其他过程。这些药物在对血浆脂质特征和颗粒大小的影响方面可能存在差异。这些药物是2型糖尿病患者口服和胰岛素治疗的优秀辅助药物，有望预防与胰岛素抵抗综合征相关的心血管疾病。目前正在进行临床试验，以确定这种治疗是否会导致心血管事件减少。
